08 February 2025 : Clinical Research
Immune Dysregulation in Acute Herpes Zoster: Predictive Factors for Postherpetic Neuralgia
Meidi Wang BCDE 1, Yanrong Yuan BCDE 1, Jun Wang ABCF 1, Yongxing Yan ACDFG 1*, Huiqin Yu ABEF 2DOI: 10.12659/MSM.944688
Med Sci Monit 2025; 31:e944688
Table 4 Baseline characteristics and comparison of humoral/cellular immune functions between HZ-PHN and HZ-control groups.
| HZ-PHN group (n=91) | HZ-control group (n=97) | t | P | |
|---|---|---|---|---|
| Age (years) | 64.6±21.4 | 55.7±21.1 | 2.875 | 0.005 |
| Sex (n, %) | ||||
| Male | 49 (54%) | 52 (53.6%) | 0.0011 | 0.9739 |
| Female | 42 (46%) | 45 (46.4%) | ||
| Disease duration (days) | 5.8±3.3 | 5.6±3.2 | 0.3397 | 0.7345 |
| Herpes location (n, %) | ||||
| Head and neck | 52 (57.1%) | 65 (67%) | 1.9451 | 0.1631 |
| Chest and back | 17 (18.7%) | 11 (11%) | 1.9963 | 0.1577 |
| Waist | 11 (12.0%) | 13 (13%) | 0.0728 | 0.7873 |
| Limbs | 9 (9.8%) | 6 (6%) | 0.8776 | 0.3489 |
| Disseminated | 2 (2.1%) | 2 (2%) | 0.0042 | 0.9485 |
| Combined diseases (n, %) | ||||
| Hypertension | 27 (29.7%) | 18 (19%) | 3.1852 | 0.0743 |
| Coronary heart disease | 6 (6%) | 3 (3%) | 1.2623 | 0.2612 |
| Stroke | 2 (2%) | 2 (2%) | 0.0042 | 0.9485 |
| Diabetes | 10 (11%) | 5 (5%) | 2.1768 | 0.1401 |
| C3 (g/L) | 1.2±0.2 | 1.2±0.3 | 0.5219 | 0.6024 |
| C4 (g/L) | 0.4±0.1 | 0.4±0.2 | 0.1914 | 0.8485 |
| IgA (g/L) | 2.4±1.1 | 2.2±0.9 | 1.2190 | 0.2246 |
| IgG (g/L) | 11.8±2.8 | 12.1±3.0 | 0.6702 | 0.5036 |
| IgM (g/L) | 1.1±0.9 | 1.0±0.5 | 0.4543 | 0.6502 |
| CD3+ (×10/L) | 872.0±366.0 | 1115.0±520.3 | 3.662 | 0.0003 |
| CD19+ (×10/L) | 180.2±122.4 | 206.4±145.1 | 1.326 | 0.1863 |
| CD8+ (×10/L) | 349.5±167.9 | 430.6±286.2 | 2.336 | 0.0206 |
| CD4+(×10/L) | 468.8±234.8 | 613.3±311.9 | 3.549 | 0.0005 |
| CD56+ (×10/L) | 277.0±169.6 | 246.4±136.0 | 1.363 | 0.1744 |
| CD4+/CD8+ | 1.6±0.8 | 1.9±1.3 | 2.331 | 0.0209 |